Evidence map›Paper›PMID 23038271›Full record

ReviewThe Journal of biological chemistry2012

5-HT(3) receptors.

Sarah C R Lummis

Open access · hybridAbstract readReview
In one paragraph

Review in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 148 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Atypical antipsychotic drug olanzapine inhibits 5-HTThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025
    Article
  6. Article
  7. Review
  8. Cryo-EM structure of the zinc-activated channel (ZAC) in the Cys-loop receptor superfamily.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  9. Article
  10. Structural basis for partial agonism in 5-HTNature structural & molecular biology · 2024
    Article
  11. Article
  12. Review
  13. Article
  14. 5-HTInternational journal of molecular sciences · 2023
    Article
  15. Article
  16. Article
  17. Review
  18. Cortical VIPJournal of molecular neuroscience : MN · 2022
    Article
  19. Radiotracers for the Central Serotoninergic System.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Sarah C R LummisDepartment of Biochemistry, University of Cambridge, Cambridge CB2 1QW, UK. sl120@cam.ac.uk
University of Cambridge · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

5-Hydroxytryptamine type 3 (5-HT(3)) receptors are cation-selective Cys loop receptors found in both the central and peripheral nervous systems. There are five 5-HT(3) receptor subunits (A-E), and all functional receptors require at least one A subunit. Regions from noncontiguous parts of the subunit sequence contribute to the agonist-binding site, and the roles of a range of amino acid residues that form the binding pocket have been identified. Drugs that selectively antagonize 5-HT(3) receptors (the "setrons") are the current gold standard for treatment of chemotherapy-induced and postoperative nausea and vomiting and have potential for the treatment of a range of other conditions.

Indexed as

AnimalsBinding SitesHumansReceptors, Serotonin, 5-HT3Serotonin 5-HT3 Receptor AgonistsSerotonin 5-HT3 Receptor AntagonistsReceptors, Serotonin, 5-HT3Serotonin 5-HT3 Receptor AgonistsSerotonin 5-HT3 Receptor Antagonists

Identifiers

PMID23038271
PMCPMC3504740
OpenAlexW2001273659

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.